Christopher Robert Manz, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neoplasms | 23 | 2025 | 22386 | 1.470 |
Why?
|
Prisoners | 3 | 2025 | 317 | 1.440 |
Why?
|
Communication | 11 | 2024 | 3910 | 1.310 |
Why?
|
Terminal Care | 3 | 2024 | 1773 | 1.070 |
Why?
|
Medicare | 6 | 2024 | 6881 | 0.830 |
Why?
|
Prospective Payment System | 1 | 2020 | 136 | 0.660 |
Why?
|
SEER Program | 1 | 2024 | 1476 | 0.650 |
Why?
|
Biomedical Technology | 1 | 2020 | 210 | 0.600 |
Why?
|
Equipment and Supplies | 1 | 2020 | 273 | 0.590 |
Why?
|
Drug Therapy | 1 | 2020 | 504 | 0.560 |
Why?
|
Physician-Patient Relations | 4 | 2024 | 3267 | 0.550 |
Why?
|
Patient-Centered Care | 1 | 2024 | 1439 | 0.460 |
Why?
|
Reimbursement Mechanisms | 1 | 2019 | 677 | 0.450 |
Why?
|
Life Expectancy | 1 | 2020 | 1249 | 0.440 |
Why?
|
Qualitative Research | 1 | 2024 | 3115 | 0.440 |
Why?
|
Benchmarking | 1 | 2019 | 1058 | 0.410 |
Why?
|
Outpatients | 1 | 2020 | 1607 | 0.410 |
Why?
|
Marketing | 1 | 2014 | 224 | 0.410 |
Why?
|
Caregivers | 1 | 2024 | 2302 | 0.400 |
Why?
|
Medical Oncology | 6 | 2024 | 2347 | 0.400 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2024 | 2331 | 0.390 |
Why?
|
Prisons | 2 | 2025 | 178 | 0.390 |
Why?
|
Physicians | 2 | 2024 | 4615 | 0.390 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2023 | 2040 | 0.360 |
Why?
|
Advance Care Planning | 3 | 2022 | 698 | 0.340 |
Why?
|
Immunotherapy, Adoptive | 1 | 2019 | 1505 | 0.330 |
Why?
|
Liver Neoplasms | 1 | 2024 | 4362 | 0.310 |
Why?
|
Death | 2 | 2023 | 683 | 0.310 |
Why?
|
Drug Industry | 1 | 2014 | 793 | 0.300 |
Why?
|
Humans | 36 | 2025 | 768451 | 0.240 |
Why?
|
Telemedicine | 1 | 2022 | 3104 | 0.230 |
Why?
|
United States | 9 | 2025 | 73121 | 0.230 |
Why?
|
Hospitalization | 1 | 2024 | 10845 | 0.230 |
Why?
|
Breast Neoplasms | 2 | 2022 | 21156 | 0.220 |
Why?
|
Electronic Health Records | 2 | 2024 | 4877 | 0.210 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2021 | 9425 | 0.210 |
Why?
|
Antineoplastic Agents | 2 | 2024 | 13708 | 0.200 |
Why?
|
Lung Neoplasms | 2 | 2024 | 13589 | 0.200 |
Why?
|
Quality of Life | 2 | 2023 | 13497 | 0.200 |
Why?
|
Health Services Accessibility | 1 | 2019 | 5510 | 0.190 |
Why?
|
Phenylurea Compounds | 1 | 2024 | 532 | 0.190 |
Why?
|
Colorectal Neoplasms | 1 | 2021 | 6978 | 0.190 |
Why?
|
Female | 18 | 2025 | 396943 | 0.180 |
Why?
|
Documentation | 2 | 2024 | 913 | 0.180 |
Why?
|
Aged | 11 | 2025 | 171520 | 0.170 |
Why?
|
Quinolines | 1 | 2024 | 769 | 0.160 |
Why?
|
Social Justice | 1 | 2023 | 486 | 0.150 |
Why?
|
Patient Care Planning | 1 | 2023 | 904 | 0.150 |
Why?
|
Physician's Role | 1 | 2024 | 927 | 0.140 |
Why?
|
Palliative Care | 2 | 2023 | 3644 | 0.140 |
Why?
|
Economics, Hospital | 1 | 2019 | 210 | 0.140 |
Why?
|
Middle Aged | 11 | 2025 | 223418 | 0.130 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2024 | 959 | 0.130 |
Why?
|
Male | 12 | 2025 | 364781 | 0.120 |
Why?
|
Tamoxifen | 1 | 2019 | 968 | 0.120 |
Why?
|
Diffusion of Innovation | 1 | 2019 | 730 | 0.120 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2022 | 10358 | 0.110 |
Why?
|
Adaptation, Psychological | 1 | 2024 | 2665 | 0.110 |
Why?
|
Family | 1 | 2024 | 3208 | 0.110 |
Why?
|
Administration, Oral | 1 | 2021 | 4041 | 0.110 |
Why?
|
Hospice Care | 1 | 2020 | 679 | 0.100 |
Why?
|
Inappropriate Prescribing | 1 | 2014 | 212 | 0.100 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2023 | 1755 | 0.090 |
Why?
|
Health Promotion | 1 | 2023 | 2215 | 0.090 |
Why?
|
Accidental Falls | 1 | 2019 | 1081 | 0.090 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2019 | 1536 | 0.090 |
Why?
|
Lymphoma | 1 | 2019 | 1907 | 0.090 |
Why?
|
Medication Adherence | 1 | 2021 | 2190 | 0.080 |
Why?
|
Health Status Disparities | 1 | 2021 | 1876 | 0.080 |
Why?
|
Retrospective Studies | 3 | 2024 | 81834 | 0.080 |
Why?
|
Survival Analysis | 1 | 2021 | 10125 | 0.080 |
Why?
|
Cohort Studies | 2 | 2022 | 41797 | 0.080 |
Why?
|
Early Detection of Cancer | 1 | 2023 | 3230 | 0.080 |
Why?
|
Aged, 80 and over | 2 | 2024 | 59680 | 0.070 |
Why?
|
Prospective Studies | 2 | 2022 | 54914 | 0.070 |
Why?
|
Algorithms | 3 | 2022 | 14158 | 0.070 |
Why?
|
Pharmaceutical Preparations | 1 | 2014 | 1089 | 0.070 |
Why?
|
Carcinoma, Renal Cell | 1 | 2021 | 3197 | 0.070 |
Why?
|
Prognosis | 3 | 2022 | 30028 | 0.060 |
Why?
|
Databases, Factual | 1 | 2021 | 8081 | 0.060 |
Why?
|
Antibodies, Monoclonal | 1 | 2023 | 9263 | 0.060 |
Why?
|
Healthcare Disparities | 1 | 2021 | 3412 | 0.060 |
Why?
|
Adenocarcinoma | 1 | 2023 | 6400 | 0.060 |
Why?
|
Pancreatic Neoplasms | 1 | 2023 | 5442 | 0.060 |
Why?
|
Prevalence | 1 | 2021 | 15880 | 0.060 |
Why?
|
Quality of Health Care | 1 | 2019 | 4340 | 0.060 |
Why?
|
Incidence | 1 | 2021 | 21552 | 0.050 |
Why?
|
Mucin 5AC | 1 | 2023 | 96 | 0.050 |
Why?
|
Pandemics | 1 | 2022 | 8753 | 0.050 |
Why?
|
Adult | 3 | 2025 | 223542 | 0.030 |
Why?
|
Paclitaxel | 1 | 2023 | 1737 | 0.030 |
Why?
|
Triage | 1 | 2021 | 997 | 0.030 |
Why?
|
Critical Illness | 1 | 2024 | 2754 | 0.020 |
Why?
|
Delivery of Health Care | 1 | 2023 | 5367 | 0.020 |
Why?
|
Phenotype | 1 | 2022 | 16712 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2019 | 15460 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 11843 | 0.010 |
Why?
|
Risk Assessment | 1 | 2019 | 24311 | 0.010 |
Why?
|